Tags

Type your tag names separated by a space and hit enter

Calcium antagonists in the prevention of motion sickness.
Aviat Space Environ Med. 1986 Jan; 57(1):45-8.AS

Abstract

Flunarizine is a calcium antagonist which has proved clinically useful in controlling chronic vertigo. In a double blind crossover trial 10 subjects were used to compare the electronystagmic responses to motion in patients taking flunarizine, prochlorperazine maleate, or placebo. Flunarizine is shown to be a powerful peripherally acting labyrinthine suppressant, with application in the prevention of motion sickness. Flunarizine produces none of the central depressive side effects characteristic of antihistamines and anticholinergics, which are the conventional anti-motion sickness drugs.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

3510617

Citation

Lee, J A., et al. "Calcium Antagonists in the Prevention of Motion Sickness." Aviation, Space, and Environmental Medicine, vol. 57, no. 1, 1986, pp. 45-8.
Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med. 1986;57(1):45-8.
Lee, J. A., Watson, L. A., & Boothby, G. (1986). Calcium antagonists in the prevention of motion sickness. Aviation, Space, and Environmental Medicine, 57(1), 45-8.
Lee JA, Watson LA, Boothby G. Calcium Antagonists in the Prevention of Motion Sickness. Aviat Space Environ Med. 1986;57(1):45-8. PubMed PMID: 3510617.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcium antagonists in the prevention of motion sickness. AU - Lee,J A, AU - Watson,L A, AU - Boothby,G, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 45 EP - 8 JF - Aviation, space, and environmental medicine JO - Aviat Space Environ Med VL - 57 IS - 1 N2 - Flunarizine is a calcium antagonist which has proved clinically useful in controlling chronic vertigo. In a double blind crossover trial 10 subjects were used to compare the electronystagmic responses to motion in patients taking flunarizine, prochlorperazine maleate, or placebo. Flunarizine is shown to be a powerful peripherally acting labyrinthine suppressant, with application in the prevention of motion sickness. Flunarizine produces none of the central depressive side effects characteristic of antihistamines and anticholinergics, which are the conventional anti-motion sickness drugs. SN - 0095-6562 UR - https://www.unboundmedicine.com/medline/citation/3510617/Calcium_antagonists_in_the_prevention_of_motion_sickness_ L2 - https://medlineplus.gov/motionsickness.html DB - PRIME DP - Unbound Medicine ER -